Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

BIOMARKER:

AFP elevation

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Entrez ID:

Related biomarkers:

‹

AFP elevation + VIM positive (1)

TERT mutation + AFP elevation (1)

AFP elevation + VIM positive (1)

TERT mutation + AFP elevation (1)

›

AFP elevation	Hepatocellular Cancer	AFP elevation	Hepatocellular Cancer	ramucirumab Sensitive: A1 - Approval ramucirumab Sensitive : A1	ramucirumab Sensitive: A1 - Approval ramucirumab Sensitive : A1
AFP elevation	Hepatocellular Cancer	AFP elevation	Hepatocellular Cancer	regorafenib Sensitive: B - Late Trials regorafenib Sensitive : B	regorafenib Sensitive: B - Late Trials regorafenib Sensitive : B
AFP elevation	Hepatocellular Cancer	AFP elevation	Hepatocellular Cancer	sorafenib + LY2157299 Sensitive: C2 – Inclusion Criteria sorafenib + LY2157299 Sensitive : C2	sorafenib + LY2157299 Sensitive: C2 – Inclusion Criteria sorafenib + LY2157299 Sensitive : C2
AFP elevation	Hepatocellular Cancer	AFP elevation	Hepatocellular Cancer	sorafenib Sensitive: C2 – Inclusion Criteria sorafenib Sensitive : C2	sorafenib Sensitive: C2 – Inclusion Criteria sorafenib Sensitive : C2
AFP elevation	Hepatocellular Cancer	AFP elevation	Hepatocellular Cancer	cabozantinib tablet Sensitive: C3 – Early Trials cabozantinib tablet Sensitive : C3	cabozantinib tablet Sensitive: C3 – Early Trials cabozantinib tablet Sensitive : C3
AFP elevation	Rectal Cancer	AFP elevation	Rectal Cancer	Sensitive: C3 – Early Trials Sensitive : C3	Sensitive: C3 – Early Trials Sensitive : C3
AFP elevation	Hepatocellular Cancer	AFP elevation	Hepatocellular Cancer	bevacizumab + atezolizumab Resistant: C3 – Early Trials bevacizumab + atezolizumab Resistant : C3	bevacizumab + atezolizumab Resistant: C3 – Early Trials bevacizumab + atezolizumab Resistant : C3
AFP elevation	Hepatocellular Cancer	AFP elevation	Hepatocellular Cancer	pembrolizumab Sensitive: C4 – Case Studies pembrolizumab Sensitive : C4	pembrolizumab Sensitive: C4 – Case Studies pembrolizumab Sensitive : C4
AFP elevation	Prostate Cancer	AFP elevation	Prostate Cancer	etoposide IV + bleomycin Sensitive: C4 – Case Studies etoposide IV + bleomycin Sensitive : C4	etoposide IV + bleomycin Sensitive: C4 – Case Studies etoposide IV + bleomycin Sensitive : C4